APA citiranje

(2021). Abemaciclib Improves Disease‐Free Survival in High‐Risk HR+/HER2– Early Breast Cancer. Oncologist.

Citação norma Chicago

"Abemaciclib Improves Disease‐Free Survival in High‐Risk HR+/HER2– Early Breast Cancer." Oncologist 2021.

MLA citiranje

"Abemaciclib Improves Disease‐Free Survival in High‐Risk HR+/HER2– Early Breast Cancer." Oncologist 2021.

Opozorilo: Ti citati niso vedno 100% točni.